- Home
- NXPL vs GDTC Comparison
NXPL vs GDTC Comparison
Compare NXPL & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | GDTC |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 10.4M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NXPL | GDTC |
|---|---|---|
| Price | $9.20 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 20.9K | 13.8K |
| Earning Date | 05-15-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,869,558.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $0.34 | $0.68 |
| 52 Week High | $9.94 | $3.68 |
Technical Indicators
Market Signals| Indicator | NXPL | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 47.12 |
| Support Level | $8.73 | $0.74 |
| Resistance Level | $9.91 | $1.05 |
| Average True Range (ATR) | 0.43 | 0.09 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 22.09 | 41.62 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.